Therapeutic plasma exchange for immune-mediated neurological diseases
Evaluation of Therapeutic Plasma Exchange for Immune-Mediated Neurological Diseases in a Sample of Egyptian Patients: An Experience at Al-Azhar University Hospitals
Al-Azhar University · NCT07197099
This project will see if therapeutic plasma exchange helps people in Egypt with immune-mediated neurological conditions such as Guillain-Barré syndrome, myasthenia gravis, CIDP, and multiple sclerosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Sex | All |
| Sponsor | Al-Azhar University (other) |
| Locations | 1 site (Cairo) |
| Trial ID | NCT07197099 on ClinicalTrials.gov |
What this trial studies
This is an observational, single-center project at Al-Azhar University Hospitals in Cairo collecting outcomes from patients who receive therapeutic plasma exchange (TPE) for immune-mediated neurological diseases. Adults and children who meet ASFA guidelines for TPE as first- or second-line therapy, including new and relapse cases, are included and followed for clinical response rates and functional improvement. Patients with contraindications to TPE or who do not complete at least five exchange sessions are excluded. The report will compare response and safety data to published experience to inform local practice.
Who should consider this trial
Good fit: Ideal candidates are patients of any age treated at Al-Azhar University Hospitals in Cairo who have an immune-mediated neurological disorder and meet ASFA criteria for TPE as first- or second-line therapy.
Not a fit: Patients with contraindications to TPE, those with non-neurological disorders, or those who fail to complete the prescribed five or more TPE sessions are unlikely to gain benefit from participation.
Why it matters
Potential benefit: If successful, the findings could confirm benefit and inform how TPE is used and monitored for patients with neuroimmune disorders in Egyptian clinical settings.
How similar studies have performed: Multiple decades of prior studies have shown that TPE can benefit conditions like myasthenia gravis, Guillain-Barré syndrome, and CIDP, so this work adds local outcome data rather than testing a novel therapy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. All neurological patients irrespective of age who will undergo TPE. 2.All new and relapse cases that meet the ASFA guidelines and where TPE is the first and/or second line of therapy Exclusion Criteria: * 1\. Individuals with contraindications to therapeutic plasma exchange, such as hemodynamic unstable, hypocalcaemia, allergy to fresh frozen plasma or albumin. 2.Patients who will undergo fewer than five cycles of TPE and not complete the procedure. 3.Patients with non-neurological disorders.
Where this trial is running
Cairo
- Al-Azhar University Hospitals — Cairo, Egypt (RECRUITING)
Study contacts
- Study coordinator: Wajdi Hamid Eisay, MD
- Email: wajdyessa91@gmail.com
- Phone: 00218911103885
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Neurological Autoimmune Diseases